Aim to create disease-modifying medicines that can be delivered to tissues beyond the liver, to which most gene editing treatments are currently limited.
Margrethe Sørgaard offers 25 years’ experience in leading positions in clinical development and operation, medical affairs and drug safety/pharmacovigilance.
The partnership leverages Variant Bio’s genomic discovery capabilities and VB-Inference platform as well as Evotec’s expertise in antifibrotic drug discovery.